Intravenous immunoglobulin in neurological disorders: A mechanistic perspective

Journal of Neurology, Supplement

Volumn 252, Issue 2, 2005, Pages 1-6

  Misra, Namita ^a   Bayry, Jagadeesh ^a   Ephrem, Amal ^a   Dasgupta, Suryasarathi ^a   Delignat, Sandrine ^a   Van Huyen, Jean Paul Duong ^a   Prost, Fabienne ^a   Lacroix Desmazes, Sebastien ^a   Nicoletti, Antonino ^a   Kazatchkine, Michel D ^a   Kaveri, Srini V ^a  

^a INSERM   (France)

Author keywords

Disorders; Immunoglobulin; Intravenous; Mechanisms; Neurological

Indexed keywords

AUTOANTIBODY; COMPLEMENT; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN;

ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; DENDRITIC CELL; HUMAN; IMMUNOLOGY; MYELIN SHEATH; NEUROLOGIC DISEASE; PHYSIOLOGY; REVIEW; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYELIN SHEATH; NERVOUS SYSTEM DISEASES; RECEPTORS, FC; T-LYMPHOCYTES;

EID: 23844483953     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Achiron A, Gabbay U, Hassin-Baer S, Barrk Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398-402
2. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104:10-20
3. Andersson U, Bjork L, Skansen SU, Andersson J (1994) Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139:21-42 (Pubitemid 24232670)
4. Andersson UG, Bjork L, SkansénSaphir U, Andersson JP (1993) Downregulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 79:211-216 (Pubitemid 23172214)
5. Ballow M (1997) Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100: 151-157
6. Basta M, Dalakas MC (1994) Highdose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Invest 94:1729-1735 (Pubitemid 24348207)
7. Basta M, Fries LF, Frank MM (1991) High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments on to sensitized erythrocytes. Blood 77:376-380
8. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, ' Berkower I, Stojilkovic SS, Metcalfe DD (2003) F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431-438 (Pubitemid 36460077)
9. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailiar A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758-765
10. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV (2003) Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48: 3497-3502 (Pubitemid 37531915)
11. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, Delignat S, Varambally S, Oksenhendler E, Levy Y, Debré M, Kazatchkine MD, Hermine O, Kaveri SV (2004) Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101:14210-14215 (Pubitemid 39305055)
12. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Intravenous immunoglobulin for infectious diseases: back to the preantibiotic and passive prophylaxis era? Trends Pharmacol Sci 25:306-310 (Pubitemid 38692422)
13. Bendtzen K, Hansen MB, Ross C, Svenson M (1998) High-avidity autoantibodies to cytokines. Immunol Today 19:209-211 (Pubitemid 28275571)
14. Biasczyk R, Westhoff U, Grossewilde H (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341: 789-790 (Pubitemid 23096288)
15. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-l-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573-581 (Pubitemid 36513638)
16. Crow AR, Song S, Freedman J, Melgasen CD, Humphries RK, Siminovitch KA, Lazarus AH (2003) IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIPl, SHP-l, and Btk activity. Blood 102:558-560 (Pubitemid 36841975)
17. Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721-730
18. Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. Jama 291: 2367-2375
19. Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51:2-8
20. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immune globulin for stiffperson syndrome. N Engl J Med 345: 1870-1876 (Pubitemid 33716561)
21. Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107-116
22. Fazekas F, Deisenhammer F, StrasserFuchs S, Nahler G, Mamoli B, FTAIIMSS group (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting sclerosis. Latncet 349:589-593 (Pubitemid 27101884)
23. Gelfand E, Landwehr L, Esterl B, Mazer B (1996) intravenous immune globulin: ati alternative therapy in steroiddependent allergic diseases. Clin Exp Immunol 104:61-66
24. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD (1994) Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap Immunol 1:269-278
25. Kaveri S,Vassilev T, Hurez V, Lengagne R, Cot S, Pouletty P, Glotz D, Kazatchkine M (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest 97:865-869 (Pubitemid 26057106)
26. Kazatchkine MD, Dietrich G, Hurez V, Rotida N, Bellen B, Rossi F, Kaveri SV (1994) V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139:79-107
27. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755
28. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J (1993) Immunologically active proteins in intravenous immunoglobulin. Lancet 342:678 (Pubitemid 23271513)
29. Lutz HU, Stammler P, Bianchi V, Trueb RM, Hunziker T, Burger R, Jelezarova E, Spath PJ (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level Blood 103: 465-72 (Pubitemid 38140074)
30. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schhitter SF, Yocum DE, Edmundson AB (1992) Human autoantibodies reactive with synthetic autoantigens from T-cell receptor ß chain. Proc Natl Acad Sci USA 89:3325-3329
31. Modiano JF, Amran D, Lack G, Bradley K, Ball C, Domenico J, Gelfand EW (1997) Posttranscription al regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol 83:77-85 (Pubitemid 27128399)
32. Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R (1998) High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 48:312-317 (Pubitemid 28416976)
33. Pashov A, Dubey C, Kaveri SV, Lectard B, Huang Y, Kazatchkine MD, Bellen B (1998) Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 28:1823-1831 (Pubitemid 28271698)
34. Prasad N, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV (1998) Therapeutic preparations of normal polyspecific immunoglobulin G (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781-3790
35. Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, Haeffher-Cavaillon N (1995) Selective induction ofinterleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25:1267-1273
36. Samuelsson A, Towers T, Ravetch J (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 -.484-486
37. Saoudi A, Hurez V, De KY, Kuhn J, Kaveri SV, Kazatchkine MD, Druet P, Bellon B (1993) Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats. Transplant Proc 25:2838-2839 (Pubitemid 23314261)
38. Sewell WA, Jolies S (2002) Immunomodulatory action of intra venous immunoglobulin. Immunology 107: 387-393 (Pubitemid 36693642)
39. Sharief M, Ingram D, Swash M, Thompson E (1999) I. v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 52:1833-1838 (Pubitemid 29260897)
40. Sooryanarayana V, Prasad N, Bonnin E, Pashov A.Ben-Jilani K, Ameisen JC, Kazatchkine MD, Kaveri SV (1999) Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin. Biochem Biophys Res Co mm 264: 896-901
41. Sorensen PS (2003) The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123-130
42. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Biinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50: 1273-1281 (Pubitemid 28240339)
43. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K (1998) Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in Human IgG preparations. Blood 91:2054-2061 (Pubitemid 28185508)
44. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH (2002) Multifocal motor neuropathy: longterm clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125:1875-1886
45. van Engelen BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M (1994) Promotion of remyelination by polyclonal immunoglobulin in Theiler's virusinduced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 57(Suppl):65-68 (Pubitemid 24356112)
46. Van Schaik IN, Lundkvist E, Vermeiden M, Brand A (1992) Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12:325-334
47. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD (1993) Antibodies to the CDS molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 92:369-372 (Pubitemid 23183742)
48. Vassilev T, Kazatchkine MD, Duong Van Huyen JP, Mekrache M, Bonnin E, Korinth D, Baruch D, Mani JC, Lecroubier C, Schriever F, Kaveri SV (1999) Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (Intravenous Immunoglobulin, IVIg). Blood 93:3624-3631 (Pubitemid 29249807)
49. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LF. (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493 (Pubitemid 28483679)
50. Vuist W, Van Schaik I, Van Lint M, Brand A (1997) The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol 17:301-310 (Pubitemid 27356135)
51. Warrington AE, Asakura K, Bieber A, Ciric B, Van Keulen V, Kaveri SV, Kyle RA, Pease LR, Rodriguez M (2000) Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci (USA) 97: 6820-6825 (Pubitemid 30412798)
52. Yu Z, Lennon V (1999) Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340:227-228 (Pubitemid 29063222)